Mendelian Disorders Testing Market Growth 2020 Global Analysis, Size, Share, Trends, Forecast to 2027
Mendelian disorders testing market research report: by test type (carrier testing, diagnostic testing, new-born screening), by disorder (cystic fibrosis, sickle cell anemia), by end-user (hospitals, ascs, specialized clinics) – Global forecast till 2027
Global Mendelian disorder testing Market – Overview
The Mendelian disorder is genetic disorder in humans which arises due to mutation in a single gene. Mendelian disorder can be predicted with the help of a genograms. Hemophilia, thalassemia, color blindness, cystic fibrosis, sickle cell anemia, and phenylketonuria are the most common mendelian disorders. Mendelian disorder is of four types autosomal dominant, autosomal recessive, sex-linked dominant and sex-linked recessive. Genetic testing allows diagnosis of inherited diseases, it determines the changes in chromosomes, genes, proteins and metabolites. Some of the available genetic tests are: cell free foetal DNA testing, new-born screening, prenatal diagnosis, carrier testing, preimplantation genetic diagnosis, predictive and presymptomatic testing.
Globally mendelian disorders testing market is estimated to grow at a rate of 6.5% during the forecast period.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5500
The market is going to continue with the same trends of growth during the forecast period 2017-2023. According to U.S. Department of Health and Human Services, there are 70,000 to 80000 Americans affected by sickle cell disease, an inherited blood disorder. Thousands of new-borns are detected with beta thalassemia each year. Beta thalassemia is normally affects people from Central Asia, the Middle East, India, Southeast Asia, Mediterranean countries, and North Africa. Cystic fibrosis, a genetic disease occurs in 1 in 2,500 to 3,500 US new-borns. Therefore, the major factor driving the growth of the market is increasing prevalence of mendelian diseases. Other factor include increasing technology advancement in genetic testing, increasing awareness in emerging economies for genetic testing, increasing simple, accessible procedure and various others.
Whereas, cost required for developing technology and inaccurate results may hinder the growth of the market.
Global Mendelian disorder testing Market – Competitive Analysis
There are many players of the market, but the existing players are strengthening their position in the industry by innovating technically advanced products. With well-established market, major companies like Abbott laboratories, ELITech Biomedical Systems, Thermo Fisher Scientific, Myriad Genetics Inc. and others acquire maximum market share.
Founded in 1900, Abbott laboratories discovers, develops, and markets a series of healthcare products. The company’s Diagnostic Products include diagnostic systems and tests manufactured, marketed, and sold worldwide. In August 2016, Abbott introduced Alinity, a next-generation system used to carry out immunoassay, clinical chemistry, hematology, blood and plasma screening and molecular diagnostics. With the launch of Alinity portfolio, the company will be able to offer more efficiency and flexibility to doctors and scientists and help them improve decision-making and patient care.
ELITech Biomedical Systems a well-known world leader for the diagnosis of cystic fibrosis. ELITech’s Macroduct System is a simple and accurate sweat test system available. The firm is involved in product innovation such as its research and development department has developed Nanoduct, the miniature sweat analysis system for patients of any age. This patented Nanoduct enables doctors to intervene and treat this disease at an early stage. In April, 2018 ELITechGroup, entered into an agreement with R-Biopharm, a life science company to strengthen their positions in molecular infectious disease testing market.
Thermo Fisher Scientific an American multinational biotechnology product development company, founded in 2006 by the merger of Thermo Electron and Fisher Scientific. In September, 2015, Thermo Fisher launched targeted sequencing system S5 and S5 XL systems. Thermo Fisher concentrates on targeted sequencing applications in inherited disease, oncology, reproductive health, infectious disease, and forensics. The S5 and S5 XL are research-use only products but in future Thermo Fisher plans to register them with the US Food and Drug Administration. Along with the next generation sequencing systems, Thermo Fisher also launched 13 targeted AmpliSeq panels comprising 3,000 Mendelian disease genes. Thus extending their product line.
Qiagen a leading provider of molecular diagnostics is headquartered in Germany. QIAGEN announced new GeneReader NGS chemistry is ready launch and can be used with QIAGEN’s Digital NGS. Digital NGS uses Unique Molecular Index (UMI) technology that provides accurate quantification and detection of molecular variants. This technology is reliable and detects even the rarest of mutation. Thus fuelling its innovative solutions for better results.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/mendelian-disorders-testing-market-5500
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future
+1 646 845 9312